Marinus Pharmaceuticals Provides Business Update and 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Jefferies Cuts Price Target on Marinus Pharma (MRNS) to $13 Following 4Q
March 8, 2016 8:34 AM ESTJefferies maintained a Buy rating on Marinus Pharmaceuticals (NASDAQ: MRNS), and cut the price target to $13.00 (from $14.00), following the company's 4Q. Total operating expenses for Q4 were $7.5M consisting of $6.1M of R&D and $1.4M G&A expense. MRNS is set to announce... More
Marinus Pharma (MRNS) Reports Q4 Loss of $0.45
March 7, 2016 7:35 AM ESTMarinus Pharma (NASDAQ: MRNS) reported Q4 EPS of ($0.45), versus ($0.26) reported last year.
For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.
... More